Last reviewed · How we verify
Challenge: Application of MC2-01 Cream, irradiation
Challenge: Application of MC2-01 Cream, irradiation is a Small molecule drug developed by MC2 Therapeutics. It is currently in Phase 1 development.
At a glance
| Generic name | Challenge: Application of MC2-01 Cream, irradiation |
|---|---|
| Sponsor | MC2 Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Challenge: Application of MC2-01 Cream, irradiation CI brief — competitive landscape report
- Challenge: Application of MC2-01 Cream, irradiation updates RSS · CI watch RSS
- MC2 Therapeutics portfolio CI
Frequently asked questions about Challenge: Application of MC2-01 Cream, irradiation
What is Challenge: Application of MC2-01 Cream, irradiation?
Challenge: Application of MC2-01 Cream, irradiation is a Small molecule drug developed by MC2 Therapeutics.
Who makes Challenge: Application of MC2-01 Cream, irradiation?
Challenge: Application of MC2-01 Cream, irradiation is developed by MC2 Therapeutics (see full MC2 Therapeutics pipeline at /company/mc2-therapeutics).
What development phase is Challenge: Application of MC2-01 Cream, irradiation in?
Challenge: Application of MC2-01 Cream, irradiation is in Phase 1.